Fate Therapeutics (FATE) EBITDA (2012 - 2026)
Fate Therapeutics (FATE) EBITDA from Sep 30, 2012 to Mar 31, 2026. The TTM Fate Therapeutics (FATE) EBITDA is -$127M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Fate Therapeutics (FATE) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -30.64% |
| 3 Years TTM | -19.93% |
| 5 Years TTM | -1.43% |
| 10 Years TTM | +16.49% |
| All Time TTM | +18.96% |
Annual EBITDA change of Fate Therapeutics (FATE)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$30M | -77.69% |
| 2025 | -$135M | -29.54% |
| 2024 | -$191M | +11.08% |
| 2023 | -$172M | -41.54% |
| 2022 | -$295M | +39.54% |
| 2021 | -$211M | +68.91% |
| 2020 | -$125M | +26.86% |
| 2019 | -$99M | +49.54% |
| 2018 | -$66M | +60.12% |
| 2017 | -$41M | +32.40% |
| 2016 | -$31M | +14.73% |
| 2015 | -$27M | +10.98% |
| 2014 | -$24M | +42.75% |
| 2013 | -$17M | +31.84% |
| 2012 | -$13M | +2.77% |
| 2011 | -$13M | -22.19% |
| 2010 | -$16M | +21.68% |
| 2009 | -$13M | +85.91% |
| 2008 | -$7.17M | N/A |
Comparison Fate Therapeutics (FATE) five years EBITDA CAGR with competitors
Fate Therapeutics (FATE) five years EBITDA CAGR is -1.44%.